GlassScriptPhysician profile
Pouya Shooliz
NPI 1508228529
$11,441.82
in general payments reported to CMS, 2019-2025
56 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $597 · 2021: $1,835 · 2022: $1,980 · 2023: $1,661 · 2024: $2,832 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,806.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.04 | 2021-2025 | Ubrelvy, Botox |
| Biogen, INC. | $792.77 | 2019-2025 | Skyclarys, Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $689.38 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $570.44 | 2019-2025 | Ultomiris, Soliris |
| Genentech USA, INC. | $557.61 | 2020-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $509.90 | 2020-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $485.63 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $453.20 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $419.73 | 2021-2025 | |
| Ucb, INC. | $408.27 | 2021-2025 | Fintepla, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $374.79 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Lundbeck LLC | $362.04 | 2021-2025 | Vyepti, Rexulti |
| Abbott Laboratories | $361.02 | 2023-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $343.97 | 2021-2023 | Uplizna |
| Eisai INC. | $324.30 | 2020-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pouya Shooliz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.